Study of 2141-V11 for bladder cancer that did not respond to standard treatment
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a new drug, 2141-V11, for people with bladder cancer that has not gone away after standard treatments like BCG therapy. It may help those with non-muscle invasive bladder cancer or, in one group, muscle-invasive bladder cancer, who cannot have or choose not to have bladder removal surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with high-grade non-muscle invasive bladder cancer (or muscle-invasive bladder cancer for one part) that has not responded to BCG treatment or, for some, you have not had BCG.
- Your cancer is mostly urothelial (the typical bladder cancer type) and has been confirmed by a pathologist.
- If you have tumors that can be seen with a scope, they must have been completely removed in a procedure called TURBT, and your most recent check was within the last 6 months.
- You have chosen not to have or are not able to have bladder removal surgery (cystectomy), and the doctor has confirmed this.
- Your kidneys, liver, and blood counts are within acceptable levels, and you are generally in good enough health (ECOG score of 2 or better).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment called NDV01 KIT for people with high-grade non-muscle invasive bladder cancer that hasn't gotten better after BCG therapy. It's for those who cannot or choose not to have their bladder removed.
This trial compares two combinations of chemotherapy drugs given directly into the bladder to see which works better for patients whose bladder cancer has not responded to BCG therapy.
This trial tests a combination of chemotherapy placed directly into the bladder and an immunotherapy drug called pembrolizumab (given through a vein) for people with high-risk bladder cancer that has not completely responded to or has returned after BCG treatment.
This trial tests a new study medicine called PF-08052667 for people with a certain type of bladder cancer that hasn't spread into the muscle. It's for those who have already tried BCG treatment and can't or won't have their bladder removed.
This trial studies whether bicalutamide can improve outcomes for people with non-muscle-invasive bladder cancer who are starting BCG through the bladder. It may help prevent cancer from coming back or progressing after BCG.
This study tests a new sustained-release chemotherapy (NDV-01) given directly into the bladder for people with non-muscle invasive bladder cancer that hasn't responded to BCG therapy or is at intermediate risk. It compares the new drug to standard chemotherapy to see if it can delay or prevent cancer from coming back.
Hear when a new Non Muscle Invasive Bladder Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.